Lantern Pharma Doses Initial Patients in First-In-Human Trial for LP-284
Details : LP-284 is a small molecule with a synthetically lethal mechanism, evaluated for relapsed/refractory non-Hodgkin’s lymphoma and other solid tumors.
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2024
Details : LP-284 is a novel small-molecule, next-generation acylfulvene, which is currently being evaluated for the treatment of High-Grade B-cell Lymphomas (HGBL).
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2023
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP-284 is a novel small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells that harbor mutations in DNA damage repair pathways, which is investigated for the treatment of non-hodgkin’s lymphomas.
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2023
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP-284 is a novel small molecule agent that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair pathways. Lantern is developing LP-284 for several aggressive B-cell NHL’s, including MCL and double hit lymphoma (DHL).
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 13, 2023
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
Details : LP-284 is a novel small molecule agent that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair pathways. Lantern is developing LP-284 for several aggressive B-cell NHL’s, including MCL and double hit lymphoma (DHL).
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP-284 is a novel small molecule and DNA damaging agent being developed by Lantern for the treatment of several non-Hodgkin’s lymphomas (NHL) including MCL and double hit lymphoma (DHL).
Brand Name : LP-284
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Lead Product(s) : LP-284
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?